- Home
- AQB vs RNAZ Comparison
AQB vs RNAZ Comparison
Compare AQB & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | RNAZ |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AQB | RNAZ |
|---|---|---|
| Price | $1.03 | $5.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.2K | 9.8K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $5.01 |
| 52 Week High | $2.95 | $20.99 |
Technical Indicators
Market Signals| Indicator | AQB | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 22.60 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.06 | $9.37 |
| Average True Range (ATR) | 0.07 | 0.65 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 73.80 | 13.16 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.